Articles de revue sur le cancer du sein - Dernières parutions

InTextoResearch, agence d'information scientifique


InTextoResearch vous informe sur les dernières parutions d'articles de
revue sur le cancer du sein (18 mai 2008):


Epothilones as lead structures for new anticancer drugs--pharmacology,
fermentation, and structure-activity-relationships.
Altmann KH, Memmert K.
Prog Drug Res. 2008;66:273, 275-334.

Clinical proteomics and breast cancer: strategies for diagnostic and
therapeutic biomarker discovery.
Bertucci F, Goncalves A.
Future Oncol. 2008 Apr;4(2):271-87.

Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of
the breast.
Ansari B, Ogston SA, Purdie CA, Adamson DJ, Brown DC, Thompson AM.
Br J Surg. 2008 May;95(5):547-54.

Gynaecomastia and breast cancer in men.
Niewoehner CB, Schorer AE.
BMJ. 2008 Mar 29;336(7646):709-13.

Review of the etiology of breast cancer with special attention to
organochlorines as potential endocrine disruptors.
Salehi F, Turner MC, Phillips KP, Wigle DT, Krewski D, Aronson KJ.
J Toxicol Environ Health B Crit Rev. 2008 Mar;11(3-4):276-300.

The emerging role of lapatinib in HER2-positive breast cancer.
Ulhoa-Cintra A, Greenberg L, Geyer CE.
Curr Oncol Rep. 2008 Jan;10(1):10-7.

Ixabepilone, a novel epothilone analog in the treatment of breast
cancer.
Pivot X, Villanueva C, Chaigneau L, Nguyen T, Demarchi M, Maurina T,
Stein U, Borg C.
Expert Opin Investig Drugs. 2008 Apr;17(4):593-9.

Vinflunine: clinical perspectives of an emerging anticancer agent.
Yun-San Yip A, Yuen-Yuen Ong E, Chow LW.
Expert Opin Investig Drugs. 2008 Apr;17(4):583-91.

Ixabepilone for the treatment of solid tumors: a review of clinical
data.
Denduluri N, Swain SM.
Expert Opin Investig Drugs. 2008 Mar;17(3):423-35.

Preoperative therapy as a model for translational research in breast
cancer.
Burstein HJ.
Cancer Invest. 2008 Apr-May;26(3):217-21.

Aromatase inhibitors for breast cancer: different structures, same
effects?
Ponzone R, Mininanni P, Cassina E, Pastorino F, Sismondi P.
Endocr Relat Cancer. 2008 Mar;15(1):27-36.

The role of locoregional therapy in inflammatory breast cancer.
Woodward WA, Buchholz TA.
Semin Oncol. 2008 Feb;35(1):78-86.

The medical treatment of inflammatory breast cancer.
Dawood S, Ueno NT, Cristofanilli M.
Semin Oncol. 2008 Feb;35(1):64-71.

Defining the molecular biology of inflammatory breast cancer.
Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F.
Semin Oncol. 2008 Feb;35(1):41-50.

Denosumab: RANKL inhibition in the management of bone loss.
Hamdy NA.
Drugs Today (Barc). 2008 Jan;44(1):7-21.

From single- to multi-target drugs in cancer therapy: when
aspecificity becomes an advantage.
Petrelli A, Giordano S.
Curr Med Chem. 2008;15(5):422-32.

Zoledronic acid: a pharmacoeconomic review of its use in the
management of bone metastases.
McKeage K, Plosker GL.
Pharmacoeconomics. 2008;26(3):251-68.

Development of new targeted therapies for breast cancer.
Doyle DM, Miller KD.
Cancer Treat Res. 2008;141:119-34.

HER-2 and topoisomerase II as predictors of response to chemotherapy.
Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-
Thind B.
J Clin Oncol. 2008 Feb 10;26(5):736-44.

Is there a role for positron emission tomography in breast cancer
staging?
Hodgson NC, Gulenchyn KY.
J Clin Oncol. 2008 Feb 10;26(5):712-20.

Drug transporters: recent advances concerning BCRP and tyrosine kinase
inhibitors.
Lemos C, Jansen G, Peters GJ.
Br J Cancer. 2008 Mar 11;98(5):857-62.

Trastuzumab as the lead monoclonal antibody in advanced breast cancer:
choosing which patient and when.
Olver IN.
Future Oncol. 2008 Feb;4(1):125-31.


(contact pour InTextoResearch: Marc Lacroix, Baelen, Wallonie,
Belgique - scimedweb@mail.com)